Clinical trials: Orbital Edema
Periorbital Hyperpigmentation, Periorbital Edema
A 12 Week Study to Evaluate the Efficacy of an Eye Cream
This single center, open-label clinical study was conducted to assess the efficacy and tolerance of a topical eye cream when used over the course of 12 weeks by healthy women with moderate to severe under-eye dark circles…
- Conditions
- Periorbital Hyperpigmentation, Periorbital Edema, Fine Lines, Wrinkle
- Trial name
- NCT05807620
- Testing
- Gentle Cleansing Lotion, Facial Moisturizer, Sunscreen SPF 30
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Revision Skincare
Rhinoplasty, Ecchymosis
Intra-operative Nasal Compression After Lateral Osteotomy to Minimize Post-operative Peri-orbital Ecchymosis and Edema
Periorbital edema and ecchymosis are common morbidities in the post-operative period after rhinoplasty. Lateral osteotomy techniques used to reshape the bony nasal pyramid are large contributing factors to the degree of bruising…
- Trial name
- NCT02319954
- Testing
- Direct compression
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Thyroid Eye Disease
A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)
The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).
- Trial name
- STRIVE (NCT06384547)
- Testing
- Veligrotug
- Where
- 50 sites in United States, Australia and 5 more
- Volunteers
- 231 people
- Sponsor
- Viridian Therapeutics, Inc.
Neurological Disorder, Nursing Caries
Effects of Cold Application and Heparinoid on Periorbital Edema and Ecchymosis
During surgery, blood leaking from damaged blood vessels spread to the periorbital area may cause periorbital edema and ecchymosis after anterior craniotomy.
- Conditions
- Neurological Disorder, Nursing Caries, Periorbital Edema, Ecchymosis
- Trial name
- NCT04119297
- Testing
- Routine care, Cold gel pack, Heparinoids Topical Cream
- Volunteers
- 90 people
- Sponsor
- Necmettin Erbakan University
Thyroid Eye Disease
An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, veligrotug (VRDN-001), in participants with chronic thyroid eye disease (TED).
- Trial name
- THRIVE-2 (NCT06021054)
- Testing
- Veligrotug
- Where
- 57 sites in United States, Australia and 7 more
- Volunteers
- 188 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid Eye Disease (TED)
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).
- Trial name
- NCT06812325
- Testing
- VRDN-003
- Where
- 64 sites in United States, France and 5 more
- Volunteers
- 320 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid Eye Disease
An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301
The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).
- Trial name
- OLE (NCT06179875)
- Testing
- Veligrotug
- Where
- 45 sites in United States, France and 6 more
- Volunteers
- 139 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid Eye Disease
An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab
This is a clinical trial to evaluate the safety and efficacy of veligrotug (LUMVOA™) in participants with moderate to severe TED who previously received and responded to an initial course of teprotumumab treatment but…
- Trial name
- NCT07832136
- Testing
- veligrotrug (LUMVOA™)
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid Eye Disease
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid Eye Disease (TED).
- Trial name
- REVEAL-2 (NCT06625398)
- Testing
- VRDN-003
- Where
- 60 sites in United States, Germany and 4 more
- Volunteers
- 204 people
- Sponsor
- Viridian Therapeutics, Inc.
Orbital Edema, Orbital Ecchymosis
The Effect of Local and Systemic Tranexamic Acid on Edema and Ecchymosis in Orbital Surgery
Tranexamic acid (TXA) is a synthetic reversible competitive inhibitor to plasminogen lysine receptor, which prevents plasmin formation and stabilizes the fibrin matrix, thus reducing bleeding.
- Trial name
- NCT06450392
- Testing
- Tranexamic acid injection, Tranexamic Acid in NaCl,Iso-Os 1,000 Mg/100 mL (10 Mg/mL) INTRAVEN INTRAVENOUS SOLUTION, PIGGYBACK (ML), normal saline - injection
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Montefiore Medical Center
Thyroid Eye Disease
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).
- Trial name
- REVEAL-1 (NCT06625411)
- Testing
- VRDN-003
- Where
- 48 sites in United States, Germany and 3 more
- Volunteers
- 132 people
- Sponsor
- Viridian Therapeutics, Inc.
Uveitis, Conjunctivitis
Ocular Manifestations in Rheumatic Diseases
This is a search strategy for determining the prevalence of ocular complications in inflammatory rheumatic diseases for the purposes of a meta analysis.
- Conditions
- Uveitis, Conjunctivitis, Keratoconjunctivitis Sicca, Xerophthalmia
- Trial name
- NCT03753893
- Testing
- No intervention used
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Thyroid Eye Disease
A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)
The investigational drug, veligrotug (VRDN-001), is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).
- Trial name
- THRIVE (NCT05176639)
- Testing
- Veligrotug
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 113 people
- Sponsor
- Viridian Therapeutics, Inc.
Periorbital Edema
Energy-Based Lower Eyelid Rejuvenation - Proof of Concept for InMode AccuTite With or Without Morpheus8
1. To establish clinical efficacy, safety and patient satisfaction of reducing lower eyelid convexities or "bags" and/or malar crescents (festoons) with catheter-based injectable RF (InMode AccuTite) and variable depth Fractional…
- Trial name
- NCT04103619
- Testing
- AccuTite, AccuTite + Morpheus 8
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- InMode MD Ltd.
TNF-receptor Associated Periodic Syndromes (TRAPS)
Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).
This trial will assess the safety and efficacy of ACZ885 in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS).
- Trial name
- NCT01242813
- Testing
- ACZ885
- Where
- 6 sites in Ireland, Italy and 1 more
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals